Mark Throsby

Mark Throsby has been working in the field since 1994, beginning with a Post-Doctoral Fellowship at the University of Toronto. Mark then moved to a position as an Associate Investigator at CNRS UMR8603 Universite Paris V, Hopital Necker in 1995. In 2000, they accepted a role as Director of Antibody Discovery and Sr. Scientist at Crucell. In 2008, they became the Chief Operating Officer at Merus Biopharmaceuticals B.V., and in 2013 they were promoted to Chief Scientific Officer at Merus. In 2020, they began working as a Healthcare Consultant at Chiton Rocks BV, Interim Chief Scientific Officer at Montis Biosciences BV, and COO/CSO at Gadeta. Most recently, in 2021, they accepted the role of Executive Chairman at Alethiomics and Director at ONA Therapeutics.

Mark Throsby completed their Ph.D. in Immunology at Monash University between 1985 and 1994. Prior to this, they attended Geelong Grammer School from 1979 to 1984.